Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Genmab A (GNMSF) Invested Capital (2023 - 2025)

Historic Invested Capital for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $11.1 billion.

  • Genmab A's Invested Capital rose 11648.82% to $11.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.1 billion, marking a year-over-year increase of 11648.82%. This contributed to the annual value of $11.1 billion for FY2025, which is 11648.82% up from last year.
  • As of Q4 2025, Genmab A's Invested Capital stood at $11.1 billion, which was up 11648.82% from $5.8 billion recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Invested Capital peaked at $11.1 billion during Q4 2025, and registered a low of $4.4 billion during Q2 2024.
  • For the 3-year period, Genmab A's Invested Capital averaged around $5.8 billion, with its median value being $5.2 billion (2024).
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 960.1% in 2024, then soared by 11648.82% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Invested Capital stood at $4.7 billion in 2023, then grew by 9.6% to $5.1 billion in 2024, then soared by 116.49% to $11.1 billion in 2025.
  • Its Invested Capital was $11.1 billion in Q4 2025, compared to $5.8 billion in Q3 2025 and $5.3 billion in Q2 2025.